We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

VEDA LAB

VEDALAB focuses on the development, production and marketing of in vitro immunodiagnostic reagents and instruments. I... read more Featured Products: More products

Download Mobile App





Vedalab Exhibits Rapid Diagnostic Tests

By LabMedica International staff writers
Posted on 11 Nov 2024
Print article
Image: Vedalab is exhibiting at MEDICA 2024 at booth number n°1A64, Hall 1 (Photo courtesy of Vedalab)
Image: Vedalab is exhibiting at MEDICA 2024 at booth number n°1A64, Hall 1 (Photo courtesy of Vedalab)

Vedalab (Cerisé, France) is showcasing its wide range of rapid diagnostic tests at the MEDICA exhibition from November 11th to 14th, 2024 being held in Dusseldorf, Germany.

Vedalab offers a wide range of immunochromatographic rapid tests which are being highlighted at the trade fair. This includes the new Vitamin D-CHECK-1 immunochromatographic rapid test for the quantitative determination of Vitamin D in plasma or serum samples and the Toxo IgG-CHECK-1 immunochromatographic rapid test for the qualitative detection of IgG antibodies to Toxoplasma gondii in whole blood, plasma or serum samples. Vedalab’s quantitative rapid tests are designed for use on its EASY READER+ instrument showcased at MEDICA 2024. This POC reader enables quantitative measurements from finger-prick whole blood samples using rapid lateral flow tests. The instrument includes the most advanced and up-to-date technologies such as touch screen, enhanced memory, and internet upgrading. The EASY READER+ and quantitative rapid tests are designed for healthcare professionals, for use in physician’s offices, clinical laboratories, and online pharmacies, and for consumers through organizations that provide diagnostic information.

Vedalab’s EASY READER+ and quantitative rapid tests are widely used as screening tools for various medical conditions and diseases. Vedalab is also highlighting its range of immunochromatographic rapid tests for the quantitative detection of AFP (alpha-fetoprotein), beta chain specific hCG (human chorionic gonadotrophin), C-peptide, CA 125 (ovarian cancer antigen), Cancer Antigen 15-3 (CA 15-3), Cancer Antigen 19-9 (CA 19-9), Calprotectin, CEA (carcinoembryonic antigen), Creatine Kinase MB isoenzyme, Cortisol, C-reactive protein, and D-DIMER in whole blood, serum, urine or plasma samples. These tests generate accurate, rapid, and cost-effective diagnostic information for acute and chronic conditions affecting men's and women's health at various stages of life.

Related Links:
Vedalab

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The study validated the Lumipulse p-tau21 automated and scalable blood test system (Photo courtesy of Fujirebio)

Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy

Alzheimer's disease (AD) is a debilitating condition and a leading cause of disability and death worldwide. The availability of reliable diagnostic tools is currently restricted, and diagnosis often relies... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.